James E Flynn Insider Trading $NGSX NeurogesX Inc
Get free email notifications about insider trading for James E Flynn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James E Flynn. James E Flynn is 10% Owner in CAS MEDICAL SYSTEMS INC ($CAMY.OB) and 10% Owner in AxoGen, Inc. ($LECT) and 10% Owner in PAR PHARMACEUTICAL COMPANIES, INC. ($PRX) and 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in STREAMLINE HEALTH SOLUTIONS INC. ($LANV) and 10% Owner in ANTARES PHARMA, INC. ($ATRS) and 10% Owner in VIA Pharmaceuticals, Inc. ($CAQ) and 10% Owner in DUSA PHARMACEUTICALS INC ($DUSA) and 10% Owner in HI TECH PHARMACAL CO INC ($HITK) and 10% Owner in AVADEL PHARMACEUTICALS PLC ($AVDL) and 10% Owner in INSPIRE PHARMACEUTICALS INC ($ISPH) and 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and 10% Owner in ARENA PHARMACEUTICALS INC ($ARNA) and 10% Owner in ISTA PHARMACEUTICALS INC ($ISTA) and 10% Owner in MEDICINES CO /DE ($MDCO) and 10% Owner in THIRD WAVE TECHNOLOGIES INC /WI ($TWTI) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in Cyclacel Pharmaceuticals, Inc. ($CYCC) and Director in Talon Therapeutics, Inc. ($EMLR) and 10% Owner in LUMOS PHARMA, INC. ($NLNK) and 10% Owner in NITROMED INC ($NTMD) and 10% Owner in XENOPORT INC ($XNPT) and 10% Owner in EMAGEON INC ($EMAG) and 10% Owner in CATALYST BIOSCIENCES, INC. ($CBIO) and 10% Owner in ALIMERA SCIENCES INC ($ALIM) and 10% Owner in NeuroMetrix, Inc. ($NURO) and 10% Owner in NxStage Medical, Inc. ($NXTM) and 10% Owner in aTYR PHARMA INC ($LIFE) and 10% Owner in Vanda Pharmaceuticals Inc. ($VNDA) and 10% Owner in XERIS PHARMACEUTICALS INC ($XERS) and Director in PROTEON THERAPEUTICS INC ($PRTO) and 10% Owner in eHealth, Inc. ($EHTH) and 10% Owner in ZAFGEN, INC. ($ZFGN) and 10% Owner in NeurogesX Inc ($NGSX) and 10% Owner in Invuity, Inc. ($IVTY) and 10% Owner in Dicerna Pharmaceuticals Inc ($DRNA) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and 10% Owner in TriVascular Technologies, Inc. ($TRIV) and 10% Owner in Auspex Pharmaceuticals, Inc. ($ASPX) and 10% Owner in Neos Therapeutics, Inc. ($NEOS) and 10% Owner in Schrodinger, Inc. ($SDGR) and 10% Owner in CytomX Therapeutics, Inc. ($CTMX) and Director in Acutus Medical, Inc. ($AFIB) and 10% Owner in Annexon, Inc. ($ANNX) and 10% Owner in Aclaris Therapeutics, Inc. ($ACRS) and 10% Owner in Syros Pharmaceuticals, Inc. ($SYRS) and 10% Owner in Mallinckrodt plc ($MNK) and 10% Owner in Loxo Oncology, Inc. ($LOXO) and 10% Owner in Adverum Biotechnologies, Inc. ($AAVL) and 10% Owner in REGENXBIO Inc. ($RGNX) and 10% Owner in Recro Pharma, Inc. ($REPH) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and Director in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in ShockWave Medical, Inc. ($SWAV) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and 10% Owner in Editas Medicine, Inc. ($EDIT) and Director in AveXis, Inc. ($AVXS) and 10% Owner in ARVINAS INC. ($ARVN) and 10% Owner in Homology Medicines, Inc. ($FIXX) and Director in Homology Medicines, Inc. ($FIXX) and Director in Oncorus, Inc. ($ONCR) and 10% Owner in Revolution Medicines, Inc. ($RVMD) and 10% Owner in Black Diamond Therapeutics, Inc. ($BDTX) and 10% Owner in Frequency Therapeutics, Inc. ($FREQ) and Director in DFB Healthcare Acquisitions Corp. ($DFBH) and 10% Owner in Generation Bio Co. ($GBIO) and 10% Owner in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM) and 10% Owner in Cabaletta Bio, Inc. ($CABA) and 10% Owner in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in Nkarta, Inc. ($NKTX) and 10% Owner in Edgewise Therapeutics, Inc. ($EWTX) and Director in DFP HEALTHCARE ACQUISITIONS CORP. ($DFPH) and Director in Deerfield Healthcare Technology Acquisitions Corp. ($DFHT) and 10% Owner in Terns Pharmaceuticals, Inc. ($TERN).
James E Flynn in NeurogesX Inc
Trading Symbol: NGSXIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of James E Flynn: 10% Owner
Holdings: 987,880 shares
Latest Transaction: Jul 15 2009
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of James E Flynn in NeurogesX Inc
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACRS, AFIB, DFBH, ADVM, ALIM, ALPN, ANNX, ATRS, ARNA, ARVN, LIFE, BOLD, ASPX, AVDL, AVXS, LECT, BDTX, CABA, CAMY.OB, CBIO, CNST, CYCC, CTMX, DFHTW, DFPHU, DRNA, DUSA, DVAX, EWTX, EDIT, EHTH, EMAG, FCSC, FREQ, GBIO, HITK, FIXX, ISPH, IVTY, ISTA, KNSA, LRMR, LOXO, NLNK, MNK, MDCO, MIRM, NEOS, NGSX, NURO, NTMD, NKTX, NXTM, ONCR, PRX, TARA, REPH, RGNX, RVMD, RYTM, RIGL, SDGR, SWAV, STDY, LANV, SYRS, EMLR, TERN, TWTI, TRIV, VNDA, CAQ, HOWL, XNPT, XERS
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jul 15 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.97 | 162,600 | 970,722 | 987,880 | 1.2 M to 987.9 K (-14.13 %) |
Jul 15 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.97 | 87,552 | 522,685 | 537,701 | 625.3 K to 537.7 K (-14.00 %) |
Jul 10 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.97 | 6,501 | 38,811 | 1,150,480 | 1.2 M to 1.2 M (-0.56 %) |
Jul 10 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.97 | 3,499 | 20,889 | 625,253 | 628.8 K to 625.3 K (-0.56 %) |
Jul 10 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.89 | 8,902 | 52,433 | 1,156,981 | 1.2 M to 1.2 M (-0.76 %) |
Jul 10 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.89 | 4,792 | 28,225 | 628,752 | 633.5 K to 628.8 K (-0.76 %) |
Jul 08 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.96 | 19,404 | 115,648 | 1,165,883 | 1.2 M to 1.2 M (-1.64 %) |
Jul 08 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.96 | 10,447 | 62,264 | 633,544 | 644 K to 633.5 K (-1.62 %) |
Jul 08 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.90 | 15,990 | 94,341 | 1,185,287 | 1.2 M to 1.2 M (-1.33 %) |
Jul 08 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.90 | 8,609 | 50,793 | 643,991 | 652.6 K to 644 K (-1.32 %) |
Jul 01 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.99 | 10,247 | 61,380 | 1,201,277 | 1.2 M to 1.2 M (-0.85 %) |
Jul 01 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.99 | 5,517 | 33,047 | 652,600 | 658.1 K to 652.6 K (-0.84 %) |
Jul 01 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.86 | 164,444 | 963,642 | 1,211,524 | 1.4 M to 1.2 M (-11.95 %) |
Jul 01 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.86 | 3,745 | 21,946 | 1,375,968 | 1.4 M to 1.4 M (-0.27 %) |
Jul 01 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.86 | 89,327 | 523,456 | 658,117 | 747.4 K to 658.1 K (-11.95 %) |
Jul 01 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.86 | 2,033 | 11,913 | 747,444 | 749.5 K to 747.4 K (-0.27 %) |
Jun 25 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.87 | 1,519 | 8,917 | 1,379,713 | 1.4 M to 1.4 M (-0.11 %) |
Jun 25 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.73 | 6,035 | 34,581 | 1,381,232 | 1.4 M to 1.4 M (-0.44 %) |
Jun 25 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.87 | 825 | 4,843 | 749,477 | 750.3 K to 749.5 K (-0.11 %) |
Jun 25 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.73 | 3,278 | 18,783 | 750,302 | 753.6 K to 750.3 K (-0.43 %) |
Jun 25 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 6.08 | 3,305 | 20,094 | 1,387,267 | 1.4 M to 1.4 M (-0.24 %) |
Jun 25 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 6.10 | 16,200 | 98,820 | 1,390,572 | 1.4 M to 1.4 M (-1.15 %) |
Jun 25 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 6.05 | 3,750 | 22,688 | 1,406,772 | 1.4 M to 1.4 M (-0.27 %) |
Jun 25 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 6.08 | 1,795 | 10,914 | 753,580 | 755.4 K to 753.6 K (-0.24 %) |
Jun 25 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 6.10 | 8,800 | 53,680 | 755,375 | 764.2 K to 755.4 K (-1.15 %) |
Jun 25 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 6.05 | 2,037 | 12,324 | 764,175 | 766.2 K to 764.2 K (-0.27 %) |
Jun 25 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.90 | 5,744 | 33,890 | 1,410,522 | 1.4 M to 1.4 M (-0.41 %) |
Jun 25 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 6.77 | 17,445 | 118,103 | 1,416,266 | 1.4 M to 1.4 M (-1.22 %) |
Jun 25 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 5.90 | 3,119 | 18,402 | 766,212 | 769.3 K to 766.2 K (-0.41 %) |
Jun 25 2009 | NGSX | NeurogesX Inc | Flynn James E | 10% Owner | Sell | S | 6.77 | 9,475 | 64,146 | 769,331 | 778.8 K to 769.3 K (-1.22 %) |
Page: 1